Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574

Published: Thursday, January 31, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Phase 1/2a trial in CLL/SLL patients met primary and secondary objectives.

MorphoSys AG and US-based Xencor, Inc. have announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical journal Blood.

MOR208 showed encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The data support further development of the compound. Based on these results, MorphoSys plans to commence phase 2 studies of MOR208 in B-cell malignancies in the near future.

"We are very pleased with the data which justify advancing into phase 2 development in B-cell malignancies," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG.

Schottelius continued, "Given that the participants in the trial had received a median of four prior therapies, the overall response rate that we observed is very encouraging. In addition, the favorable toxicity profile will potentially allow combinations with other active agents. The results of the phase 1/2a study show us that we are on the right track with our most advanced proprietary compound in cancer."

The phase 1/2a trial was designed to assess the drug's safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity.

MOR208 was administered as an intravenous infusion on days 1, 4, 8, 15, and 22 of cycle 1, and on days 1, 8, 15, and 22 of cycle 2. Dose levels tested ranged from 0.3 to 12 mg/kg.

Among the 27 evaluable patients, three partial responses were observed at the 6, 9, and 12 mg/kg dose levels. In addition, 22 patients experienced stable disease and only two patients progressed at the 8 week evaluation point.

Clinical responses were assessed according to International Working Group on CLL (IWCLL) 2008 and 1996 Guidelines. Overall response rate by IWCLL 2008 criteria was 11% which utilizes more rigorous CT scan reduction of internal lymph nodes not previously required in older historic studies.

Using IWCLL 1996 response criteria resulted in a response rate of 42%. The most common adverse events were mild to moderate infusion reactions usually with the first dose.

Treatment-related adverse events classified as grade 3 or higher occurred in 5 out of 27 patients. Only one dose-limiting toxicity was observed in 16 patients treated at the 12 mg/kg dose level and the trial protocol was amended to include a period of extended dosing with a total of 8 patients at this dose.

"MOR208 was safe and well-tolerated in this first-in-human study, and shows promise as an novel immunotherapy for B-cell malignancies", commented the principal investigator of the study John C. Byrd, MD, Professor and D Warren Brown Chair of Leukemia Research at The James Cancer Hospital and Solove Research Institute. "We are really looking forward to incorporating this together with other active immune and targeted therapies used for CLL in the near future."

Final phase 1/2a data was presented at the 2012 American Society of Hematology (ASH) annual meeting from December 8-11, 2012 in Atlanta.

"MOR208 is now well positioned to advance in development into additional B-cell malignancies," said Bassil Dahiyat, Ph.D., Chief Executive Officer of Xencor. "The combination of tolerability and anti-tumor activity add to the growing body of clinical data on our XmAb® technology for enhancing antibody cytotoxic potency."

In June 2010, MorphoSys AG and Xencor signed a worldwide exclusive license and collaboration agreement. The agreement provided MorphoSys with an exclusive worldwide license to MOR208 for the treatment of cancer and other indications.

Using Xencor's XmAb® Fc enhancement technology, MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

MorphoSys will be solely responsible for further clinical development after successful completion of the phase 1/2a clinical trial.

MorphoSys plans to initiate additional clinical trials for MOR208 in non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL) by year-end.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys to Receive Milestone Payment for Guselkumab Program
Company initiates phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody.
Tuesday, April 14, 2015
MorphoSys Nominates Three New Candidates for Supervisory Board
Company has nominated Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich.
Tuesday, March 31, 2015
MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration
MorphoSys regains rights to MOR202 antibody against CD38 and updates its financial guidance for 2015.
Friday, March 27, 2015
MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
Early-stage portfolio now fully Ylanthia-based, includes programs with Merck Serono as well as first anti-GPCR programs.
Tuesday, July 29, 2014
MorphoSys Strengthens Clinical Development Organization with Three Management Appointments
Appointment of Dr. Gabriele Elbl, Dr. Ludger Langer and Dr. Steffen Heeger.
Monday, December 23, 2013
MorphoSys Announces Additional Clinical Trial of MOR208
Phase 2 study in CLL will evaluate MOR208 in combination with lenalidomide.
Wednesday, December 11, 2013
MorphoSys Strengthens European Patent Position on Anti-CD19 Cancer Program MOR208
New patent has a scheduled expiry date in 2027.
Tuesday, December 03, 2013
MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208
New patent covers the antibody's protein sequence.
Tuesday, October 22, 2013
MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
Extended treatment resulted in higher overall response rate.
Tuesday, October 08, 2013
MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
MorphoSys to receive clinical milestone payment.
Thursday, October 03, 2013
MorphoSys Receives Two Phase 2 Milestone Payments from Janssen
MOR202 in phase 1/2a trial for multiple myeloma.
Tuesday, September 17, 2013
MorphoSys Closes on the Alliance with Celgene for MOR202 and Increases Financial Guidance
Celgene acquires 3.4 % equity stake via a capital increase.
Monday, August 12, 2013
MorphoSys AG Reports Results for the First Six Months of 2013
Results strongly impacted by MOR103 licensing agreement with GSK.
Monday, August 05, 2013
MorphoSys and Celgene Create Strategic Alliance
Development of novel therapeutic antibody approach being evaluated in clinical trials for patients with multiple myeloma.
Thursday, June 27, 2013
Scientific News
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos